Steve Edgett
CEO | Genomadix
Kanata, ON, CANADA
Steve Edgett has more than 20 years of experience in business development, strategic planning, and international markets.
Biography
Steve serves as Genomadix’s CEO after having led the acquisition of Genomadix Bioscience in 2022. Previously, Edgett held the role of Executive Vice President of Genomadix Bioscience where he oversaw corporate strategy and international business development. Steve has more than 20 years of experience in business development, strategic planning, and international markets. He has founded and held senior leadership roles in several high-technology companies, including Knowmadics, Cobham PLC, EMS Technologies and Honeywell International.
Steve holds an Honours Bachelor of Applied Science in Systems Design Engineering from the University of Waterloo.
Industry Expertise (2)
Corporate Leadership
International Trade and Development
Areas of Expertise (6)
Communications Technologies
International Markets
Strategic Planning
New Markets
Business Strategy
Business Development
Education (1)
University of Waterloo: BaSc, Systems Design Engineering 1996
Multimedia
Publications:
Documents:
Videos:
Audio/Podcasts:
Links (1)
Selected Media Appearances (8)
‘Significant milestone’: FDA approves Genomadix’s rapid genetic-testing device for sale in U.S.
Ottawa Business Journal online
2023-03-23
CEO Steve Edgett called it a “significant milestone” for Genomadix, which is trying to gain traction after the firm that originally invented the product collapsed amid a failed effort to adapt the device as a rapid COVID-19 test.
Genomadix Announces FDA Clearance to Market Genomadix Cube CYP2C19 System
Yahoo! Finance online
2023-03-22
"The Genomadix Cube CYP2C19 System empowers physicians to make informed decisions on appropriate drug selection for a number of precision medicine indications such as antiplatelet therapy in both stroke and cardiology patients," said Steve Edgett, Genomadix's Chief Executive Officer. "This achievement represents a milestone for Genomadix. Genomadix is excited to commence precision medicine commercialization activities in the United States."
Ottawa startups remain bullish on fundraising despite headwinds in VC market
Ottawa Business Journal online
2022-12-08
Chief executive Steve Edgett said the company is polishing up its pitch deck as it prepares to pursue a “proper series-A” round aimed at raising between $25 million and $30 million in the first half of 2023. “It’s an attractive market,” Edgett says of the current fundraising climate for biotech firms like Genomadix, which makes a rapid COVID-testing device. “There’s quite a bit of money on the sidelines available to finance companies into a growth stage.”
Mayo Clinic acquires equity stake in rapid COVID test-maker Genomadix
Ottawa Business Journal online
2022-08-30
“I think the really exciting thing for us is that this provides access to some of the top clinicians in the world in a number of areas,” Genomadix chief executive Steve Edgett told Techopia on Tuesday.
Rising from Spartan’s ashes: Genomadix says retooled rapid COVID test ready for market
Ottawa Business Journal online
2022-07-21
Genomadix CEO Steve Edgett said the funding should carry the young firm through the next couple of years as it looks to get Spartan’s COVID-19 testing technology back on track after the device gained and then lost Health Canada approval over concerns about the effectiveness of its proprietary cheek swab.
Genomadix Announces Securing Two Years of Funding
Newswire online
2022-07-19
"Completing financing for Genomadix's seed round is an exciting milestone. It positions us to successfully reach our value creation plan over the next two years and establish Genomadix as a market leader," commented Steve Edgett, Genomadix's CEO. "With the support of our investors, the company is funded to deliver solutions to the market in precision medicine, point of care diagnostics and environmental monitoring. Having an institutional life sciences venture capital firm as our lead investor underscores the potential for Genomadix's success and we could not be more pleased to be part of the ICW Ventures portfolio."
Q&A: New CEO has high hopes for Spartan Cube after family trust buys biotech firm’s COVID-testing IP
Ottawa Business Journal online
2021-09-24
Now, Spartan’s technology will carry on under new owners and new leadership. OBJ recently spoke with Genomadix CEO Steve Edgett, who joined Spartan as an executive vice-president in 2019, about the challenges of trying to develop a COVID-19 test on the fly, the Spartan Cube’s future market prospects and other opportunities for the new company.
Spartan Bioscience Now Genomadix Inc.
Genomadix online
2021-09-21
“We are excited to have acquired Spartan’s disruptive technology platform, and are honored to be able to continue this noble mission to improve access to this life saving technology. Genomadix is committed to delivering on quality and excellence while continuing to innovate in point of care diagnostics and testing in the field” says Steven Edgett, CEO of Genomadix Inc.
Social